Using PDOX to guide chemotherapy after liver cancer surgery
Official title: Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Run by Zhujiang Hospital · NCT05766605 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if using a special lab-grown model of liver cancer can help doctors choose the best chemotherapy for patients after they have surgery for liver cancer.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Zhujiang Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05766605 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 who have undergone radical surgical resection for hepatocellular carcinoma and meet specific health criteria.
✕Probably not a fit
Patients with recurrent liver cancer or those with existing distant metastases will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized controlled trial evaluates the clinical feasibility of PDOX (Patient-Derived Orthotopic Xenograft) results in determining the use of interventional chemotherapy following radical surgery for primary liver cancer. Patients who have undergone radical surgical resection for hepatocellular carcinoma will be enrolled and treated with various chemotherapy agents, including Oxaliplatin and Doxorubicin. The primary endpoint is the one-year disease-free survival rate, while secondary endpoints include the assessment of adverse events. Data will be collected from patients receiving PDOX to inform treatment decisions post-surgery.
Why it matters
Potential benefit: If successful, this approach could improve disease-free survival rates for patients with hepatocellular carcinoma after surgery.
How similar studies have gone: While the use of PDOX in guiding chemotherapy is a novel approach, similar studies have shown promise in other cancer types, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Undergone radical surgical resection. 2. Aged 18-75. 3. Patients voluntarily cooperated with the study and signed an informed consent form. 4. Histopathologically diagnosed hepatocellular carcinoma. 5. Patients with R0 resection confirmed by imaging and pathology (no residual lesions and complete tumor resection after radical surgery). 6. Child-Pugh score of 5-7 (A or B), patients with a score of 7 must be free of ascites. 7. ECOG physical fitness status score of 0-1. 8. No serious heart, lung, or renal dysfunction Exclusion Criteria: 1. Unable to provide specimens for PDOX testing. 2. Patients with recurrent liver cancer. 3. Developing two or more types of tumors simultaneously. 4. Patients with existing extrahepatic distant metastases. 5. Treatment with other experimental drugs or other interventions after radical resection. 6. Patients with other malignant tumors that have not been cured within 5 years. 7. Patients with non-radical resections (R1 and R2 resections). 8. Patients with residual or recurrent lesions detected on imaging within 1-2 months after surgery. 9. Died within 1 month after surgery.
Where it's running
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Mingxin Pan, Prof.
- Email: pmxwxy@sohu.com
- Phone: +8618928918216
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pre-surgery treatment with iparomlimab, tuvonralimab, and lenvatinib for liver cancer
This trial will try a 9-week pre-surgery combination of two immune antibodies (iparomlimab and tuvonralimab) plus daily lenvatinib in people with resectable hepatocellular carcinoma who are at high risk of recurrence.
-
Monitoring blood for early signs of liver cancer recurrence after treatment
This study is testing if monitoring blood for cancer DNA can help find out sooner if liver cancer comes back after treatment, so doctors can better manage care for patients.
-
Metabolic Health Trajectories in Overweight Chinese Adults
This observational study follows overweight and obese Chinese adults to see how metabolic health changes over five years and whether people stay healthy, develop diabetes, or have complications.
-
Theta-burst temporal interference stimulation to improve awareness in people with disorders of consciousness
This study will test whether theta-burst patterned temporal interference stimulation (tTIs) can help adults with recent disorders of consciousness (vegetative or minimally conscious) show more signs of awareness.
-
Probiotic LR607 with neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer
The team will try giving adults with resectable stage IB–IIIC non-small cell lung cancer a daily probiotic (Lactobacillus rhamnosus LR607) alongside neoadjuvant chemoimmunotherapy to see if it improves tumor response and is safe.
-
Low- versus high-dose nafamostat for anticoagulation during CRRT in ICU patients
This study tests whether starting nafamostat at 50 mg/h rather than 20 mg/h keeps CRRT filters from clotting longer in adult ICU patients on continuous renal replacement therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.